Cargando…
Teprotumumab: a disease modifying treatment for graves’ orbitopathy
BACKGROUND: On 21st January 2020, the FDA approved Tepezza (teprotumumab-trbw) for the treatment of active Graves’ orbitopathy (GO) in adults. This approval was based on positive results from two multinational randomised double-blind placebo-controlled clinical trials. DISCUSSION: This article discu...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334856/ https://www.ncbi.nlm.nih.gov/pubmed/32636936 http://dx.doi.org/10.1186/s13044-020-00086-7 |